Eukaryotic Cell Display Screening for Polypeptide Developability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to conveniently integrate developability screening into the early stages of polypeptide drug discovery, particularly for aspects such as solubility and avoidance of non-specific binding, leading to costly late-stage failures.
Innovation Solution
A method involving eukaryotic cell display systems to assess and enrich polypeptides based on surface presentation levels, which serves as a predictive indicator of developability characteristics like solubility, resistance to self-association, and non-specific binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptide drugs are displayed on the surface of eukaryotic cells for screening, then the ability to screen for developability is improved, but the complexity of the system increases due to the need for stable expression and proper folding in eukaryotic systems
Solution Approach 1:
The patent introduces a fusion protein system where the polypeptide drug of interest is fused to a stable scaffold protein (such as an antibody fragment or other structured protein). This intermediary fusion construct allows the polypeptide to be displayed on the eukaryotic cell surface in a stable and controlled manner, mediating between the screening goal and the complexity challenge by providing a predictable structural framework that enhances expression stability and proper folding.
2Reliability
If polypeptide drugs are screened in eukaryotic cell display systems, then the physiological relevance of screening results is improved, but the time required for screening increases due to slower eukaryotic expression and selection processes
Solution Approach 1:
The patent employs preliminary selection of polypeptide candidates through in silico modeling and in vitro screening before introducing them to the eukaryotic cell display system. This preliminary action pre-filters the candidate pool to identify those with highest developability potential, allowing the time-consuming eukaryotic expression and screening to focus only on the most promising candidates, thereby reducing overall screening time while maintaining physiological relevance.
3Productivity
If high-throughput screening is implemented in eukaryotic cell display, then the productivity of drug discovery is improved, but the measurement precision of developability parameters decreases due to throughput compromises
Solution Approach 1:
The patent segments the screening process into multiple independent assay formats, each optimized for specific developability parameters (solubility, aggregation, stability, etc.). By dividing the comprehensive developability assessment into separate modular assays that can be performed in parallel on the cell display system, the method achieves high throughput while maintaining measurement precision for each individual parameter through specialized assay conditions and readouts.
Data Source
Figure 1a
Figure 1b
Figure 1b
AI summary
Use of the surface presentation level of binders (e.g., antibodies, receptors) on cultured higher eukaryotic cells in vitro as a predictive indicator of developability characteristics, e.g., solubility, of the binders. Display libraries of higher eukaryotic cells, e.g., mammalian cells, adapted for use in screening surface-displayed binders for developability and affinity of target binding. High-throughput screening of display libraries with in-built selection for developability including binder solubility, capability to be formulated at high concentrations, low propensity for non-specific binding, and half-life. Enrichment of populations of binders for developability characteristics and/or other qualities such as target binding and affinity, by controlling cell surface presentation of binders from an inducible promoter operably linked to binder-encoding DNA.